JP2014031330A - 高血糖等改善剤 - Google Patents
高血糖等改善剤 Download PDFInfo
- Publication number
- JP2014031330A JP2014031330A JP2012172580A JP2012172580A JP2014031330A JP 2014031330 A JP2014031330 A JP 2014031330A JP 2012172580 A JP2012172580 A JP 2012172580A JP 2012172580 A JP2012172580 A JP 2012172580A JP 2014031330 A JP2014031330 A JP 2014031330A
- Authority
- JP
- Japan
- Prior art keywords
- food
- amylase inhibitor
- amylase
- drink
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 11
- 230000000246 remedial effect Effects 0.000 title abstract 2
- 239000003392 amylase inhibitor Substances 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 30
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical class C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 12
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 10
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 10
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 10
- 208000008589 Obesity Diseases 0.000 claims abstract description 10
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 10
- 235000020824 obesity Nutrition 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 18
- 235000003373 curcuma longa Nutrition 0.000 claims description 14
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 13
- 235000013976 turmeric Nutrition 0.000 claims description 13
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 244000008991 Curcuma longa Species 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 20
- 102000004139 alpha-Amylases Human genes 0.000 description 17
- 108090000637 alpha-Amylases Proteins 0.000 description 17
- 229940024171 alpha-amylase Drugs 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 16
- 244000163122 Curcuma domestica Species 0.000 description 13
- 238000000605 extraction Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 235000013361 beverage Nutrition 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000007654 immersion Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 5
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010017711 Gangrene Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000007976 Ketosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- USLKCMBGQFYUFI-UHFFFAOYSA-N dichloromethane;tribromoborane Chemical compound ClCCl.BrB(Br)Br USLKCMBGQFYUFI-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000004140 ketosis Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- -1 1,3-butylene alcohol Chemical compound 0.000 description 2
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000001746 Pancreatic alpha-Amylases Human genes 0.000 description 2
- 108010029785 Pancreatic alpha-Amylases Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- DAKZWTGWTHYJBT-FCXRPNKRSA-N (1e,6e)-1-[4-hydroxy-3-(methoxymethoxy)phenyl]-7-(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione Chemical compound C1=C(O)C(OCOC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 DAKZWTGWTHYJBT-FCXRPNKRSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- FFRFJIZJLZXEJX-YPCIICBESA-N 1-(3,4-Dihydroxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(O)C(O)=CC=2)=C1 FFRFJIZJLZXEJX-YPCIICBESA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 244000173207 Phyllanthus amarus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- MXGYVBOZRLQICP-VUSYVUDMSA-N chembl494826 Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)\C=C(/O)\C=C\C1=CC=C(O)C(OC)=C1 MXGYVBOZRLQICP-VUSYVUDMSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- VZOPRCCTKLAGPN-UHFFFAOYSA-L potassium;sodium;2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)C(O)C(O)C([O-])=O VZOPRCCTKLAGPN-UHFFFAOYSA-L 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012172580A JP2014031330A (ja) | 2012-08-03 | 2012-08-03 | 高血糖等改善剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012172580A JP2014031330A (ja) | 2012-08-03 | 2012-08-03 | 高血糖等改善剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014031330A true JP2014031330A (ja) | 2014-02-20 |
| JP2014031330A5 JP2014031330A5 (enExample) | 2015-09-10 |
Family
ID=50281469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012172580A Pending JP2014031330A (ja) | 2012-08-03 | 2012-08-03 | 高血糖等改善剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2014031330A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023213813A1 (en) * | 2022-05-03 | 2023-11-09 | Universiteit Maastricht | Compound for use in the regulation of saccharide absorption via the gastrointestinal tract and compositions thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002047699A1 (en) * | 2000-12-12 | 2002-06-20 | Kaneka Corporation | Compositions for preventing or ameliorating multiple risk factor syndromes |
| JP2009511573A (ja) * | 2005-10-13 | 2009-03-19 | ゴカラジュ, ガンガ, ラジュ | クルクマロンガ抽出物からテトラヒドロキシクルクミン濃縮フラクションおよびテトラヒドロテトラヒドロキシクルクミン濃縮フラクションを製造するプロセス |
-
2012
- 2012-08-03 JP JP2012172580A patent/JP2014031330A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002047699A1 (en) * | 2000-12-12 | 2002-06-20 | Kaneka Corporation | Compositions for preventing or ameliorating multiple risk factor syndromes |
| JP2009511573A (ja) * | 2005-10-13 | 2009-03-19 | ゴカラジュ, ガンガ, ラジュ | クルクマロンガ抽出物からテトラヒドロキシクルクミン濃縮フラクションおよびテトラヒドロテトラヒドロキシクルクミン濃縮フラクションを製造するプロセス |
Non-Patent Citations (3)
| Title |
|---|
| JPN6016014889; Journal of Food Biochemistry, 2005, Vol.29, p.278-294 * |
| JPN6016014890; International Journal of Food Sciences and Nutrition, 2011, Vol.62(7), p.740-749 * |
| JPN6016014891; Magn. Reson. Chem., 2009, Vol.47, p.902-908 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023213813A1 (en) * | 2022-05-03 | 2023-11-09 | Universiteit Maastricht | Compound for use in the regulation of saccharide absorption via the gastrointestinal tract and compositions thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102481325B (zh) | 用于预防或治疗由ampk的激活介导的与肥胖有关的疾病、且含有作为活性成分的2,5-二芳基-3,4-二甲基四氢呋喃木脂素的组合物 | |
| WO2007060992A1 (ja) | メタボリックシンドロームもしくはインスリン抵抗性症候群の予防または改善剤 | |
| JP2016537385A (ja) | サラシア組成物、それを投与することによる治療方法及びその製造方法 | |
| JP6042800B2 (ja) | トマトシドaの抽出方法 | |
| AU2004238122A1 (en) | Composition for lowering lipid in body | |
| KR101466308B1 (ko) | 지모 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 대장염 예방 또는 치료용 조성물 | |
| JP2014031330A (ja) | 高血糖等改善剤 | |
| KR101128920B1 (ko) | 지페노사이드, 이의 제조방법 및 용도 | |
| JP6460402B2 (ja) | コレステロール排出促進用医薬組成物又は食品組成物 | |
| KR20140023700A (ko) | 오배자 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 대장염 예방 또는 치료용 조성물 | |
| JP7659768B2 (ja) | 脂質分解促進剤及びこれを含む飲食品、並びに脂質分解促進用加工食品 | |
| KR101526467B1 (ko) | 산수유 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 대장염 예방 또는 치료용 조성물 | |
| KR101054943B1 (ko) | 쿠딩차 추출물로부터 항산화 활성을 갖는 페놀릭 화합물 및이를 유효성분으로 포함하는 기능성식품 | |
| JP2010126489A (ja) | リパーゼ阻害剤および肥満抑制剤 | |
| JP5186084B2 (ja) | ロボフルーツ含有サポニンとその用途 | |
| KR100648617B1 (ko) | 누룩치로부터 분리된 부들레자사포닌 ⅳ을 함유하는 염증질환의 예방 및 치료용 조성물 | |
| KR20070083898A (ko) | 췌장 기능 개선을 위한 의약 또는 음식품 | |
| JP7781386B2 (ja) | 脂質合成抑制剤及びこれを含む飲食品、脂質合成抑制用加工食品並びに発現抑制剤 | |
| JP2019172579A (ja) | サーチュイン活性促進剤 | |
| KR100406184B1 (ko) | 우렁쉥이 껍질의 아세톤 추출물을 포함하는 항 콜레스테롤조성물 | |
| JP2011132173A (ja) | キサンチンオキシダーゼ阻害剤及び尿酸生成阻害剤 | |
| US20230218701A1 (en) | Pharmaceutical composition containing saururus chinensis fraction, and preparation method thereof | |
| KR100941015B1 (ko) | 내장 지방 축적 억제제 | |
| CN104140455B (zh) | 一种结合型米糠酚苷化合物及其制备方法和用途 | |
| KR20140023862A (ko) | 산수유 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 대장염 예방 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150724 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150724 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20150724 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160426 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161025 |